FDA to Address Female Sexual Enhancement Drugs

LOS ANGELES — The topic of female sexual dysfunction — and drugs to treat it — will be front and center at an FDA meeting this month, one in a series of 20 looking at “patient-focused drug development.”

Critics have accused the Food and Drug Administration of having a gender bias, pointing out that it has approved six male-targeted drugs to help them overcome anxiety, physiology and more to get an erection, but has yet to approve a single female equivalent. 

The meeting to be held Oct. 27-28 will include statements from patients about the impact that female sexual dysfunction has had on their lives, WebMD reports. It will also include a scientific workshop to discuss how to diagnose the disorder and measure how well medications for it work.

Advocating for pharmaceutical gender inclusivity is Even the Score, a campaign that launched in June and is backed by the drug companies of at least three potential treatments for female sexual dysfunction.

A petition to the FDA posted by Even the Score on Change.org attracted more than 16,000 signatures. The petition addresses the FDA: “We urge you to work fairly and urgently toward a solution to an unmet medical need…”

Others, including the National Women’s Health Network and the American Medical Women’s Association, believe that the dearth of pharmaceutical options for women is not a gender bias, but a reflection of how much more complicated treating female sexual dysfunction can be.  

Following, they have supported the FDA’s decisions not to approve a drug for female sexual dysfunction, arguing that women may need more than a single pill to boost their libido. Viagra and Cialis target one important aspect of sex — the erection — but do not address psychological aspects of arousal, which may be key for women’s satisfaction,

Cindy Pearson, executive director of the National Women’s Health Network, says while the FDA has not been immune to gender bias, she doesn’t believe that is what’s delaying the drugs. “If it were gender bias, we would be yelling and screaming,” Pearson said. “The problem is the drugs. Our biology is so much more complicated than men’s.”

Related:  

Copyright © 2024 Adnet Media. All Rights Reserved. XBIZ is a trademark of Adnet Media.
Reproduction in whole or in part in any form or medium without express written permission is prohibited.

More News

Allure Lingerie Hires April Hoopes as Account Executive

Allure Lingerie has hired industry veteran April Hoopes as its newest account executive.

Svakom Wins Erofest 2024 Award for Pulse Galaxie

Svakom’s Pulse Galaxie was named Best Erotic Toy 2023 at Erofest 2024.

Aneros Releases 'Psy' Massager, 'Sessions' Gel

Aneros has debuted two new products: adjustable prostate massager Psy and water-based gel lubricant Sessions Gel.

Orion Rebrands 'NO:XQSE' Line as 'Fantasy by Cotelli' Collection

Orion Wholesale has rebranded its NO:XQSE line of lingerie as the Fantasy by Cotelli collection.

Eldorado Partners With Hot Octopuss for Next Facebook Live Event

Eldorado and Hot Octopuss are partnering for the next edition of the "Eldorado Presents" Facebook Live series on Tuesday, March 19 at 10 a.m. (PDT).

Liberator Debuts New Packaging for Loungers, Chaises

Liberator has introduced new packaging for its range of love loungers, chaises and other furnishings, including the Esse, Lyza, Cello, Steed and Equus Wave.

XR Brands Introduces New Vegan-Leather Queening Chairs

XR Brands has added the Pleasure Throne Oral Sex Chair and the Face Rider Queening Chair to its Master Series collection of advanced fetish and BDSM gear.

DanaMedic Signs Mexican Distro Deal With Distribuciones y Representaciones BES

DanaMedic has signed a deal with Distribuciones y Representaciones BES for its products to be distributed across Mexico.

LELO Drops V3 Version of Signature F1S Phallus Console

LELO has released the new version of its F1S pleasure console, the V3.

Spearmint Rhino Launches 'Rhino Society' Fashion Brand

Spearmint Rhino has launched a new fashion label, Rhino Society.

Show More